

Claims

1. An isolated nucleic acid molecule of 850 base pairs (bp) to 1500 bp length, comprising
 - a. an enhancer sequence element selected from SEQ ID NO 1 to 3, and
 - 5 b. a promoter sequence element of SEQ ID NO 7.
2. An isolated nucleic acid molecule of 850 base pairs (bp) to 1500 bp length, comprising
 - a. an enhancer sequence element being at least ($\geq$) 70%, particularly $\geq 75\%$, $\geq 80\%$, more particularly $\geq 85\%$, more particularly $\geq 90\%$, more particularly $\geq 95\%$, even more particularly $\geq 98\%$, most particularly 100% identical to a
10 sequence selected from SEQ ID NO 1 to 3; and
 - b. a promoter sequence element being $\geq 70\%$, particularly $\geq 75\%$, more particularly $\geq 80\%$, more particularly $\geq 85\%$, more particularly $\geq 90\%$, more particularly $\geq 95\%$, even more particularly $\geq 98\%$, most particularly 100%
15 identical to a sequence of SEQ ID NO 7;
and said isolated nucleic acid molecule has $\geq 40\%$, particularly $\geq 50\%$, more particularly $\geq 60\%$, even more particularly $\geq 70\%$, more particularly $\geq 80\%$, even more particularly $\geq 90\%$, most particularly 100% of the cone ON bipolar cell-specificity from a sequence of SEQ ID NO 13 and a cone
20 ON bipolar cell preference of $\geq 20\%$, particularly $\geq 25\%$, more particularly $\geq 30\%$, even more particularly $\geq 35\%$, more particularly $\geq 40\%$, most particularly $\geq 50\%$.
3. The isolated nucleic acid molecule according to claim 1 or claim 2, wherein the isolated molecule consists of one and only one of said enhancer sequence
25 elements, one and only one of said promoter sequence elements and optionally, a spacer separating the enhancer sequence element from the promoter sequence element.
4. The isolated nucleic acid molecule according to any one of the preceding claims comprising or consisting of a sequence selected from SEQ ID NO 11, SEQ ID
30 NO 13, and SEQ ID NO 15, or comprising or consisting of a sequence characterized by $\geq 98\%$ identity to a sequence selected from SEQ ID NO 11, SEQ ID NO 13, and SEQ ID NO 15.
5. The isolated nucleic acid molecule according to any one of the preceding claims comprising or consisting of the sequence SEQ ID NO 11 or SEQ ID NO 13, or
35 comprising or consisting of a sequence characterized by $\geq 98\%$ identity to SEQ

ID NO 11 or SEQ ID NO 13, particularly comprising or consisting of the sequence SEQ ID NO 13, or comprising or consisting of a sequence characterized by $\geq 98\%$ identity to SEQ ID NO 13.

- 5 6. A nucleic acid expression vector comprising a nucleic acid molecule according to any one of the previous claims.
7. The nucleic acid expression vector according to claim 6, wherein the nucleic acid expression vector is an adeno-associated virus vector or a recombinant adeno-associated vector (rAAV), particularly wherein the nucleic acid expression vector is a recombinant AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, 10 AAV9, AAV10, AAV11, or AAV12 vector, more particularly wherein the nucleic acid expression vector is a recombinant AAV2 vector.
8. The nucleic acid expression vector according to ~~any one of claims 6 to 9~~ claim 7, additionally comprising
- 15 a. a sequence encoding a capsid protein, and
- b. a transgene.
9. The nucleic acid expression vector according to claim 8, wherein the transgene comprises the sequence of SEQ ID NO 16.
10. An adeno-associated virion particle comprising the isolated nucleic acid molecule according to any one of claims 1 to 5 ~~or~~ the nucleic acid expression vector according to any one of claims 6 to 9.
- 20 11. A pharmaceutical composition comprising the isolated nucleic acid molecule according to any one of claims 1 to 5, the nucleic acid expression vector according to any one of claims 6 to 9, or the adeno-associated virion particle according to claim 10.
- 25 ~~1241.~~ 1241. An agent selected from the isolated nucleic acid molecule according to any one of claims 1 to 5 ~~or~~ the nucleic acid expression vector according to any one of claims 6 to 9, and the adeno-associated virion particle according to claim 10 for use as a medicament.
- 30 ~~1342.~~ 1342. Use of Aan agent selected from the isolated nucleic acid molecule according to any one of claims 1 to 5, the nucleic acid expression vector according to any one of claims 6 to 9, and the adeno-associated virion particle

according to claim 10 in the manufacture of a medicament for treating use in
~~treatment of~~ congenital stationary night blindness (CSBN1)-~~or~~, rod-cone
dystrophy, and cone-rod dystrophiesdystrophy, particularly of retinitis
pigmentosa ~~and or~~ macular degeneration.

5 1413. ~~An agent selected from the isolated nucleic acid molecule according to any~~
~~one of claims 1 to 5, the nucleic acid expression vector according to any one of~~
~~claims 6 to 9, and the adeno-associated virion particle according to claim 10,~~
~~according to claim 11 or 12~~The use according to claim 12 or claim 13, wherein the
agent is to be administered by

- 10 a. intravitreal administration, particularly by intravitreal injection, or by
 b. subretinal injection.

15